Literature DB >> 22822423

Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms.

Jeanette Woolard1, William Vousden, Steven J Moss, Arjun Krishnakumar, Melissa Vr Gammons, David G Nowak, Neil Dixon, Jason Micklefield, Astrid Spannhoff, Mark T Bedford, Matthew A Gregory, Christine J Martin, Peter F Leadlay, Ming Q Zhang, Steven J Harper, David O Bates, Barrie Wilkinson.   

Abstract

The polyketide natural product borrelidin 1 is a potent inhibitor of angiogenesis and spontaneous metastasis. Affinity biopanning of a phage display library of colon tumor cell cDNAs identified the tandem WW domains of spliceosome-associated protein formin binding protein 21 (FBP21) as a novel molecular target of borrelidin, suggesting that borrelidin may act as a modulator of alternative splicing. In support of this idea, 1, and its more selective analog 2, bound to purified recombinant WW domains of FBP21. They also altered the ratio of vascular endothelial growth factor (VEGF) isoforms in retinal pigmented endothelial (RPE) cells in favour of anti-angiogenic isoforms. Transfection of RPE cells with FBP21 altered the ratio in favour of pro-angiogenic VEGF isoforms, an effect inhibited by 2. These data implicate FBP21 in the regulation of alternative splicing and suggest the potential of borrelidin analogs as tools to deconvolute key steps of spliceosome function.

Entities:  

Year:  2011        PMID: 22822423      PMCID: PMC3399765          DOI: 10.1039/C0SC00297F

Source DB:  PubMed          Journal:  Chem Sci        ISSN: 2041-6520            Impact factor:   9.825


  33 in total

1.  Biosynthesis of the angiogenesis inhibitor borrelidin: directed biosynthesis of novel analogues.

Authors:  Steven J Moss; Isabelle Carletti; Carlos Olano; Rose M Sheridan; Michael Ward; Vidya Math; Mohammad Nur-E-Alam; Alfredo F Braña; Ming Qiang Zhang; Peter F Leadlay; Carmen Méndez; José A Salas; Barrie Wilkinson
Journal:  Chem Commun (Camb)       Date:  2006-05-11       Impact factor: 6.222

2.  Searching for a wrench to throw into the splicing machine.

Authors:  Melissa S Jurica
Journal:  Nat Chem Biol       Date:  2008-01       Impact factor: 15.040

3.  The anti-borrelia effect of borrelidin.

Authors:  M BUCK; A C FARR; R J SCHNITZER
Journal:  Trans N Y Acad Sci       Date:  1949-04

4.  Borrelidin is an angiogenesis inhibitor; disruption of angiogenic capillary vessels in a rat aorta matrix culture model.

Authors:  T Wakabayashi; R Kageyama; N Naruse; N Tsukahara; Y Funahashi; K Kitoh; Y Watanabe
Journal:  J Antibiot (Tokyo)       Date:  1997-08       Impact factor: 2.649

5.  VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression.

Authors:  Jeanette Woolard; Wen-Ying Wang; Heather S Bevan; Yan Qiu; Lucia Morbidelli; Rowan O Pritchard-Jones; Tai-Gen Cui; Marto Sugiono; Elizabeth Waine; Rachel Perrin; Rebecca Foster; Jonathon Digby-Bell; Jacqueline D Shields; Cheryl E Whittles; Rosey E Mushens; David A Gillatt; Marina Ziche; Steven J Harper; David O Bates
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.

Authors:  David O Bates; Tai-Gen Cui; Joanne M Doughty; Matthias Winkler; Marto Sugiono; Jacqueline D Shields; Danielle Peat; David Gillatt; Steven J Harper
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Authors:  Yoshihiko Kotake; Koji Sagane; Takashi Owa; Yuko Mimori-Kiyosue; Hajime Shimizu; Mai Uesugi; Yasushi Ishihama; Masao Iwata; Yoshiharu Mizui
Journal:  Nat Chem Biol       Date:  2007-07-22       Impact factor: 15.040

8.  The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.

Authors:  Es Rennel; E Waine; H Guan; Y Schüler; W Leenders; J Woolard; M Sugiono; D Gillatt; Es Kleinerman; Do Bates; Sj Harper
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

9.  Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.

Authors:  Dawid G Nowak; Jeanette Woolard; Elianna Mohamed Amin; Olga Konopatskaya; Moin A Saleem; Amanda J Churchill; Michael R Ladomery; Steven J Harper; David O Bates
Journal:  J Cell Sci       Date:  2008-10-15       Impact factor: 5.285

10.  Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma.

Authors:  R O Pritchard-Jones; D B A Dunn; Y Qiu; A H R Varey; A Orlando; H Rigby; S J Harper; D O Bates
Journal:  Br J Cancer       Date:  2007-06-26       Impact factor: 7.640

View more
  12 in total

1.  Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.

Authors:  Eva Maria Novoa; Noelia Camacho; Anna Tor; Barrie Wilkinson; Steven Moss; Patricia Marín-García; Isabel G Azcárate; José M Bautista; Adam C Mirando; Christopher S Francklyn; Sònia Varon; Miriam Royo; Alfred Cortés; Lluís Ribas de Pouplana
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

2.  Aminoacyl-tRNA synthetase dependent angiogenesis revealed by a bioengineered macrolide inhibitor.

Authors:  Adam C Mirando; Pengfei Fang; Tamara F Williams; Linda C Baldor; Alan K Howe; Alicia M Ebert; Barrie Wilkinson; Karen M Lounsbury; Min Guo; Christopher S Francklyn
Journal:  Sci Rep       Date:  2015-08-14       Impact factor: 4.379

3.  Exploring monovalent and multivalent peptides for the inhibition of FBP21-tWW.

Authors:  Lisa Maria Henning; Sumati Bhatia; Miriam Bertazzon; Michaela Marczynke; Oliver Seitz; Rudolf Volkmer; Rainer Haag; Christian Freund
Journal:  Beilstein J Org Chem       Date:  2015-05-11       Impact factor: 2.883

Review 4.  Pharmacology of Modulators of Alternative Splicing.

Authors:  David O Bates; Jonathan C Morris; Sebastian Oltean; Lucy F Donaldson
Journal:  Pharmacol Rev       Date:  2017-01       Impact factor: 25.468

5.  A new role for FBP21 as regulator of Brr2 helicase activity.

Authors:  Lisa M Henning; Karine F Santos; Jana Sticht; Stefanie Jehle; Chung-Tien Lee; Malte Wittwer; Henning Urlaub; Ulrich Stelzl; Markus C Wahl; Christian Freund
Journal:  Nucleic Acids Res       Date:  2017-07-27       Impact factor: 16.971

Review 6.  Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.

Authors:  L M Gallego-Paez; M C Bordone; A C Leote; N Saraiva-Agostinho; M Ascensão-Ferreira; N L Barbosa-Morais
Journal:  Hum Genet       Date:  2017-04-03       Impact factor: 4.132

7.  Secreted Threonyl-tRNA synthetase stimulates endothelial cell migration and angiogenesis.

Authors:  Tamara F Williams; Adam C Mirando; Barrie Wilkinson; Christopher S Francklyn; Karen M Lounsbury
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

8.  Detection of VEGF-A(xxx)b isoforms in human tissues.

Authors:  David O Bates; Athina Mavrou; Yan Qiu; James G Carter; Maryam Hamdollah-Zadeh; Shaney Barratt; Melissa V Gammons; Ann B Millar; Andrew H J Salmon; Sebastian Oltean; Steven J Harper
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

Review 9.  Alternative splicing for diseases, cancers, drugs, and databases.

Authors:  Jen-Yang Tang; Jin-Ching Lee; Ming-Feng Hou; Chun-Lin Wang; Chien-Chi Chen; Hurng-Wern Huang; Hsueh-Wei Chang
Journal:  ScientificWorldJournal       Date:  2013-05-22

Review 10.  Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.

Authors:  Virginie Chesnais; Olivier Kosmider; Frederik Damm; Raphael Itzykson; Olivier A Bernard; Eric Solary; Michaela Fontenay
Journal:  Oncotarget       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.